(Q51784812)

English

JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders.

scientific article published in November 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

12 April 2018

http://europepmc.org/abstract/MED/16998940

JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders. (English)

1 reference

Europe PubMed Central

12 April 2018

http://europepmc.org/abstract/MED/16998940

1 reference

based on heuristic

inferred from title

Francesco Passamonti

2

1 reference

Europe PubMed Central

12 April 2018

http://europepmc.org/abstract/MED/16998940

3

1 reference

Europe PubMed Central

12 April 2018

http://europepmc.org/abstract/MED/16998940

5

1 reference

Europe PubMed Central

12 April 2018

http://europepmc.org/abstract/MED/16998940

1

object named as

Elisa Rumi

1 reference

Europe PubMed Central

12 April 2018

http://europepmc.org/abstract/MED/16998940

7

object named as

Chiara Elena

1 reference

Europe PubMed Central

12 April 2018

http://europepmc.org/abstract/MED/16998940

Cristiana Pascutto

9

object named as

Cristiana Pascutto

1 reference

Europe PubMed Central

12 April 2018

http://europepmc.org/abstract/MED/16998940

Mario Lazzarino

10

object named as

Mario Lazzarino

1 reference

Europe PubMed Central

12 April 2018

http://europepmc.org/abstract/MED/16998940

Emanuela Boveri

8

object named as

Emanuela Boveri

1 reference

Europe PubMed Central

12 April 2018

http://europepmc.org/abstract/MED/16998940

6

object named as

Sabrina Boggi

1 reference

Europe PubMed Central

12 April 2018

http://europepmc.org/abstract/MED/16998940

author name string

Matteo G Della Porta

4

1 reference

Europe PubMed Central

12 April 2018

http://europepmc.org/abstract/MED/16998940

Mario Cazzola

11

1 reference

Europe PubMed Central

12 April 2018

http://europepmc.org/abstract/MED/16998940

language of work or name

0 references

publication date

1 November 2006

1 reference

Europe PubMed Central

12 April 2018

http://europepmc.org/abstract/MED/16998940

1 reference

Europe PubMed Central

12 April 2018

http://europepmc.org/abstract/MED/16998940

107

1 reference

Europe PubMed Central

12 April 2018

http://europepmc.org/abstract/MED/16998940

2206-2211

1 reference

Europe PubMed Central

12 April 2018

http://europepmc.org/abstract/MED/16998940

9

1 reference

Europe PubMed Central

12 April 2018

http://europepmc.org/abstract/MED/16998940

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22240

21 January 2018

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22240

7 January 2021

based on heuristic

inferred from DOI database lookup

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22240

7 January 2021

based on heuristic

inferred from DOI database lookup

A gain-of-function mutation of JAK2 in myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22240

7 January 2021

based on heuristic

inferred from DOI database lookup

Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22240

7 January 2021

based on heuristic

inferred from DOI database lookup

The World Health Organization (WHO) classification of the myeloid neoplasms

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22240

7 January 2021

based on heuristic

inferred from DOI database lookup

Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22240

7 January 2021

based on heuristic

inferred from DOI database lookup

Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22240

7 January 2021

based on heuristic

inferred from DOI database lookup

Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22240

7 January 2021

based on heuristic

inferred from DOI database lookup

Polycythemia vera in identical twins

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22240

7 January 2021

based on heuristic

inferred from DOI database lookup

Familial myeloproliferative syndrome.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22240

7 January 2021

based on heuristic

inferred from DOI database lookup

Familial polycythemia vera in father and daughter

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22240

7 January 2021

based on heuristic

inferred from DOI database lookup

Clonal hematopoiesis in familial polycythemia vera suggests the involvement of multiple mutational events in the early pathogenesis of the disease

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22240

7 January 2021

based on heuristic

inferred from DOI database lookup

Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22240

7 January 2021

based on heuristic

inferred from DOI database lookup

The JAK2V617F mutation is acquired secondary to the predisposing alteration in familial polycythaemia vera

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22240

7 January 2021

based on heuristic

inferred from DOI database lookup

Lessons from familial myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22240

7 January 2021

based on heuristic

inferred from DOI database lookup

The Italian Consensus Conference on Diagnostic Criteria for Myelofibrosis with Myeloid Metaplasia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22240

7 January 2021

based on heuristic

inferred from DOI database lookup

Unbalanced X-chromosome inactivation in haemopoietic cells from normal women.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22240

7 January 2021

based on heuristic

inferred from DOI database lookup

Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22240

7 January 2021

based on heuristic

inferred from DOI database lookup

Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22240

7 January 2021

based on heuristic

inferred from DOI database lookup

JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22240

7 January 2021

based on heuristic

inferred from DOI database lookup

X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22240

7 January 2021

based on heuristic

inferred from DOI database lookup

Discordant distribution of JAK2V617F mutation in siblings with familial myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22240

7 January 2021

based on heuristic

inferred from DOI database lookup

The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22240

7 January 2021

based on heuristic

inferred from DOI database lookup

Mutation screening for JAK2V617F: when to order the test and how to interpret the results.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22240

7 January 2021

based on heuristic

inferred from DOI database lookup

The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22240

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.22240

1 reference

Europe PubMed Central

12 April 2018

http://europepmc.org/abstract/MED/16998940

1 reference

Europe PubMed Central

12 April 2018

http://europepmc.org/abstract/MED/16998940

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51784812&oldid=1857606136"